Description

Pfizer’s competitive quality improvement program supports independent initiatives that improve and standardize care for people with multiple myeloma receiving BCMA-targeting bispecific antibodies in Germany. It aims to move treatment from specialized centers into routine clinical practice through better care coordination, use of existing healthcare resources, and local patient management pathways.

Projects should apply existing knowledge to improve care rather than conduct clinical research. Priorities include standardized outpatient processes and patient selection, safety and infection management, nurse-led monitoring, and existing digital or AI-supported tools for symptom tracking and timely escalation. The program also supports replicable care models, academic–community collaboration, remote monitoring, and patient and caregiver education. The primary audience is healthcare professionals focused on multiple myeloma, including hematologists, specialty nurses, and pharmacists.